This content is restricted.
Brief
On "10/10/2024", the French National Agency for the Safety of Medicines and Health Products (ANSM) issued an update regarding Flecainide extended-release (ER) drugs being available again due to tension easing. The recommendation for replacing LP forms directly with LI or magistrales is no longer in effect. On "04/12/2023", ANSM improved the availability of Flecainide ER drugs. Due to return of LP forms, it's advised not to associate LP and LI in a single dispensation. The French National Agency for the Safety of Medicines and Health Products (ANSM) has set up a specific protocol for distributing Flécaïnide LP for patients with certain heart rhythm disorders.
Highlights content goes here...
This content is restricted.
RADA.AI
Hello! I'm RADA.AI - Regulatory Analysis and Decision Assistance. Your Intelligent guide for compliance and decision-making. How can i assist you today?
Suggested
